Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SUV39H2 | Q9H5I1 | 7/20 | 0.48 |
| ▸ | CTSK | P43235 | 2/20 | 0.46 |
| ▸ | F10 | P00742 | 1/20 | 0.46 |
| ▸ | PIM1 | P11309 | 1/20 | 0.46 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.46 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.45 |
| ▸ | KDM4D | Q6B0I6 | 3/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.43 |
| ▸ | CKS1B | P61024 | 1/20 | 0.43 |
| ▸ | SKP1 | P63208 | 1/20 | 0.43 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1350984 | 1.00 | SUV39H2 (0.48) | SUV39H2CTSKF10PIM1PIM3 | |
| SCHEMBL6486070 | 0.91 | SUV39H2 (0.50) | SUV39H2CTSKF10PIM1PIM3 | |
| SCHEMBL1350092 | 0.91 | SUV39H2 (0.49) | SUV39H2CTSKF10PIM1PIM3 | |
| SCHEMBL1350090 | 0.91 | SUV39H2 (0.49) | SUV39H2CTSKF10PIM1PIM3 | |
| SCHEMBL25453975 | 0.88 | SUV39H2 (0.55) | SUV39H2CTSKPIM1PIM3PIM2 | |
| SCHEMBL31124502 | 0.87 | SUV39H2 (0.47) | SUV39H2CTSKF10PIM1PIM3 | |
| SCHEMBL28603267 | 0.87 | SUV39H2 (0.47) | SUV39H2CTSKF10PIM1PIM3 | |
| SCHEMBL13466330 | 0.87 | PIM1 (0.48) | SUV39H2CTSKF10PIM1PIM3 | |
| SCHEMBL28603266 | 0.87 | SUV39H2 (0.47) | SUV39H2CTSKF10PIM1PIM3 | |
| SCHEMBL7235725 | 0.87 | SUV39H2 (0.48) | SUV39H2CTSKPIM1PIM3PIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063078-B2 | Urea-compounds active as vanilloid receptor antagonists for the treatment of pain | GLAXOSMITHKLINE LLC (US) | 2011-11-22 | — | — | US | disclosed |
| EP-2298757-A2 | Urea compounds active as vanilloid receptor antagonist for the treatment of pain | Glaxo Group Limited (GB) | 2011-03-23 | — | — | EP | disclosed |
| US-20090163506-A1 | Urea-compounds active as vanilloid receptor antagonists for the treatment of pain | SMITHKLINE BEECHAM PLC. (GB) | 2009-06-25 | — | — | US | disclosed |
| EP-2036902-A2 | Urea compounds active as vanilloid receptor antagonist for the treatment of pain | Glaxo Group Limited (GB) | 2009-03-18 | — | — | EP | disclosed |
| EP-1392651-A1 | HETEROCYCLIC UREAS, THEIR PREPARATION AND THEIR USE AS VANILLOID RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002090326-A1 | HETEROCYCLIC UREAS, THEIR PREPARATION AND THEIR USE AS VANILLOID RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163506-A1 | Urea-compounds active as vanilloid receptor antagonists for the treatment of pain | TRPV1, OPRL1, UTS2R | SUV39H2 2096/4885CTSK 3250/4885F10 1208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.